Altimmune Inc (NASDAQ:ALT) Reports Decline in Sellers; Strong Momentum for Longs

June 17, 2018 - By Adrian Mccoy

The stock of Altimmune Inc (NASDAQ:ALT) registered a decrease of 24.83% in short interest. ALT’s total short interest was 777,900 shares in June as published by FINRA. Its down 24.83% from 1.03M shares, reported previously. With 444,300 shares average volume, it will take short sellers 2 days to cover their ALT’s short positions. The short interest to Altimmune Inc’s float is 8.83%.

The stock decreased 2.08% or $0.011 during the last trading session, reaching $0.518. About 207,775 shares traded. Altimmune, Inc. (NASDAQ:ALT) has declined 88.88% since June 17, 2017 and is downtrending. It has underperformed by 101.45% the S&P500.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $11.53 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

Altimmune, Inc. (NASDAQ:ALT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: